B-cell Non-Hodgkin lymphoma is a heterogeneous group of malignancies such as mantle cell lymphoma, chronic lymphocytic leukemia/small
lymphocytic lymphoma, follicular lymphoma, and hairy cell leukemia. This diverse spectrum of B-cell malignancies, together with the recent
introduction of targeted therapies and immune-cell engineering, has resulted in an unprecedented choice of tolerable and effective therapeutic
options for B-cell malignancies, including BTK inhibitors, BCL2 inhibitors, and monoclonal antibodies, among others. Given the rapidity of discovery,
many clinicians who treat patients with B-cell malignancies have yet to develop the body of knowledge needed to best incorporate these agents
into practice, or how to recognize and appropriately manage the toxicities associated with these agents. As front-line caregivers, it is imperative
that oncology nurses have a fundamental knowledge of these novel agents, their place in therapy, and their associated toxicities in order to provide
the best care for their patients.

This ONS Chapter series is based on a tumor board model, in which faculty will present patient cases and lead discussions regarding proposed
treatment approaches based on the latest trial data and patient- and tumor-specific factors. Attendees will gain knowledge regarding how to
incorporate these novel therapies into clinical practice and address barriers to their use in B-cell malignancies, including patient adherence and
management of drug-associated toxicities. This ONS Chapter series will draw attendees into the process of peer discussion and encourage the
promotion of collaborative exchange with other members of their oncology care team to ensure optimal patient outcomes.



Katherine Byar, MSN, ANP-BC, BMTCN

Gynecologic Oncology Nurse Practitioner
University of Nebraska Medical Center
Omaha, Nebraska View Full Bio


In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing (ANCC)

This activity is designated for 1.0 contact hour.

 Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Upon completion of a CNE request form, statements of credit for nurses will be issued within 30 business days.

ONCC/ILNA Certification Information

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. OCN®, AOCNP®, AOCNS®, CBCN®, CPHON®, and BMTCN® nurses may apply 1.0 point in Diagnosis and Staging, Professional Practice, Scientific Basis for Practice, and Treatment categories.

Disclaimer: ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.


Supported by an independent educational grant from AstraZeneca.